The following peptides represent the strongest candidates based on mechanism complementarity, safety profiles, and documented outcomes from the research community
Monitoring recommendations: Baseline investigations: Full blood count, B12 level, folate, and intrinsic factor antibodies (if pernicious anaemia suspected) During initial treatment: Potassium monitoring in severe deficiency (risk of hypokalaemia) Follow-up: Repeat full blood count after 8 weeks to confirm haematological response Long-term: Annual review to ensure compliance with maintenance injections
(Native, unmodified recombinant human IGF-1, sold as mecasermin/Increlex, is FDA-approved only for a narrow pediatric growth-failure indication and is chemically distinct from the LR3 analog.) In the US it is manufactured and sold almost exclusively as an unregulated "research chemical" labeled "not for human consumption," a labeling practice peptide vendors use to avoid marketing it as an unapproved drug
Some patients see noticeable changes on the scale
Low dead space syringes are available and reduce this waste significantly